Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Search
Striving to revolutionize mental health research
World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Could decentralised trials transform the way we view depression?
Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure
Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
Consumer Health Data Privacy Statement
This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease